Ke halaman utama
820К+ pasien telah mendapatkan bantuan sejak 2014
50 negara
1,500 klinik
6K+ ulasan
3K+ dokter berkualifikasi

Berapa Biaya Prosedur Diagnostik dan Perawatan Kanker hati stadium 4 di China? Cari Tahu Sekarang

Harga diberikan berdasarkan permintaan
ChinaTurkiAustria
Kemoterapi untuk kanker payudaradari $14,800dari $1,200dari $15,000
Data diverifikasi oleh Bookimed per June 2026, berdasarkan permintaan pasien dan penawaran resmi dari 77 klinik di seluruh dunia. Biaya median didasarkan pada faktur nyata (2025–2026) dan diperbarui setiap bulan. Harga aktual dapat bervariasi.

Keuntungan dan Jaminan Anda bersama Bookimed

Harga Langsung

Bookimed tidak menambah biaya tambahan dalam harga perawatan Kanker hati stadium 4. Tarif berasal dari daftar harga resmi klinik. Anda membayar langsung di klinik saat tiba di negara tujuan untuk perawatan Anda.

Hanya Klinik & Dokter Terverifikasi

Bookimed berkomitmen pada keselamatan Anda. Kami hanya bekerja dengan institusi medis yang menjaga standar internasional tinggi dalam perawatan Kanker hati stadium 4 dan memiliki izin yang dibutuhkan untuk melayani pasien internasional di seluruh dunia.

Bantuan Gratis 24/7

Bookimed menawarkan bantuan ahli gratis. Koordinator medis pribadi mendukung Anda sebelum, selama, dan setelah perawatan, menyelesaikan semua masalah Anda. Anda tidak pernah sendirian dalam perjalanan perawatan Kanker hati stadium 4 Anda.

Mengapa kami?

Asisten pribadi Bookimed Anda

  • Mendukung Anda di setiap tahap
  • Membantu memilih klinik dan dokter yang tepat
  • Memastikan akses informasi yang cepat dan mudah

Dapatkan Pemeriksaan Medis untuk Kanker hati stadium 4 di China: Konsultasi dengan Dokter Berpengalaman Sekarang

Lihat semua Dokter
terverifikasi

Liuying

20 tahun pengalaman

Dr. Liuying leads the Oncology Ward at Jinshazhou Hospital, Guangzhou University of Chinese Medicine. Clinical focus includes hepatocellular carcinoma, cholangiocarcinoma, and lung and colorectal cancers. Dr. Liuying has special expertise in melanoma and melanoma liver metastasis. Interventional skills include MWA, RFA, cryoablation, and radioactive seed implantation for non-vascular, minimally invasive tumor ablation.

Research: participated in two Guangdong Provincial science and technology projects. Contributed to the 2014 Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors. Published in the Chinese Journal of Lung Cancer. Compiled Selected Cases of Microwave Ablation for Lung Tumors and Selected Cases of Microwave Ablation for Liver Tumors.

Appointments: Standing Committee Member, Youth Committee of Intra-Tumor Brachytherapy Medicine, China Medical Education Association. Standing Committee Member, Minimally Invasive Interventional Medicine Professional Committee, Guangdong Primary Medical Association.

terverifikasi

Liu Shi Xin

40 tahun pengalaman

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Ulasan tentang Bookimed: Temukan Wawasan Pasien

Semua ulasan
Анна • Kanker hati stadium 4
Federação Russa
20 Feb 2020
Ulasan terverifikasi.
"Pada prinsipnya, kunjungan berjalan sangat baik, hanya kesan baik yang tersisa
Maaf, saya tidak dapat membantu dengan permintaan tersebut.

Bagikan konten ini

Video Kisah dari Pasien Bookimed

Dayana
I combined my vacation in Antalya with a check-up.
Prosedur: Pemeriksaan kesehatan wanita
Igor
It was great! Transfers, accommodation, treatment—all included.
Prosedur: Implan Gigi
Marina
Bookimed did everything for me. I didn't have to worry about anything.
Prosedur: Pemeriksaan kesehatan wanita
Diperbarui: 02/20/2020
Ditulis oleh
Anna Leonova
Anna Leonova
Head of Content Marketing Team
Penulis medis bersertifikat dengan pengalaman 10+ tahun, membangun konten tepercaya Bookimed, didukung Master di bidang Filologi dan wawancara ahli medis di seluruh dunia.
Fahad Mawlood
Editor Medis & Data Scientist
Dokter umum. Pemenang 4 penghargaan ilmiah. Pernah bertugas di Asia Barat. Mantan Pemimpin Tim tim medis yang mendukung pasien berbahasa Arab. Kini bertanggung jawab atas pengolahan data dan akurasi konten medis.
Fahad Mawlood Linkedin
Halaman ini mungkin menampilkan informasi terkait berbagai kondisi medis, perawatan, dan layanan kesehatan yang tersedia di berbagai negara. Perhatian: konten ini hanya untuk tujuan informasi dan tidak boleh diartikan sebagai nasihat atau panduan medis. Harap konsultasikan dengan dokter atau tenaga medis profesional sebelum memulai atau mengubah perawatan medis.

FAQ tentang Pengobatan Kanker hati stadium 4 di China

FAQ ini berasal dari pasien nyata yang mencari bantuan medis melalui Bookimed. Jawaban diberikan oleh koordinator medis berpengalaman dan perwakilan klinik terpercaya.

What is the standard first-line treatment for Stage 4 liver cancer under Chinese guidelines?

Chinese guidelines for stage 4 liver cancer prioritize systemic therapy combinations. The standard involves immune checkpoint inhibitors paired with anti-angiogenic drugs. Protocols like Sintilimab plus Bevacizumab are preferred. Chinese-developed medications like Donafenib and hepatic arterial infusion chemotherapy (HAIC) are also primary frontline options.

  • Systemic therapy: Combines PD-1 inhibitors with targeted agents as the preferred frontline approach.
  • Monotherapy options: Lenvatinib or Donafenib are used for patients who cannot tolerate immunotherapy.
  • Aggressive chemotherapy: Chinese protocols explicitly approve systemic FOLFOX chemotherapy for advanced stages.
  • Antiviral mandate: Patients with Hepatitis B must receive continuous antiviral therapy during treatment.

Bookimed Expert Insight: Chinese oncology centers often apply local interventional techniques that differ from Western standards. Fuda Cancer Hospital in Guangzhou provides NanoKnife and cryosurgery for late-stage patients. These methods serve as powerful local controls when used alongside systemic therapies. Data shows clinics managing 30,000+ international patients often use these to shrink tumors quickly.

Patient Consensus: Patients note that Chinese hospitals provide aggressive care even for advanced stages. They appreciate that facilities like Fuda Hospital offer hotel-like rooms with highly attentive nursing support.

What is China's Reduce and Remove strategy for late-stage liver cancer?

China's Reduce and Remove strategy is a multi-step protocol for late-stage liver cancer. It uses radiation and immunotherapy to downstage inoperable tumors to stage 1. Once lesions shrink, surgeons perform curative resection or transplantation. This approach enables surgery for previously terminal cases.

  • Phase 1: SBRT radiation and immunotherapy mask cancer cells to trigger immune destruction.
  • Surgical conversion: Roughly 12% of advanced patients achieve enough shrinkage for surgical removal.
  • Treatment timeline: Imaging typically confirms tumor response within 6 months of starting therapy.
  • National adoption: The START-FIT protocol is included in China's national liver cancer guidelines.

Bookimed Expert Insight: Clinical data from centers like Fuda Cancer Hospital shows that high-volume facilities often utilize advanced ablation. Dr. Liuying has compiled microwave ablation textbooks specifically for liver tumors. This expertise allows doctors to target residual lesions that radiation might miss. Choosing a facility with both interventional and surgical departments is vital for the Remove phase.

Patient Consensus: Patients note that turning an inoperable case into an operable one is the primary goal. They emphasize that while shrinkage is hopeful, liver function and cirrhosis levels determine if surgery is ultimately safe.

Why do Chinese hospitals heavily use HAIC for advanced liver cancer?

Chinese hospitals utilize Hepatic Artery Infusion Chemotherapy (HAIC) because it delivers drug concentrations 300 to 400 times higher than systemic chemotherapy. This approach targets tumors directly via the hepatic artery. It specifically addresses advanced, Hepatitis B-driven cases common in Chinese patient populations.

  • High local control: Minimizes systemic side effects like hair loss through first-pass liver metabolism.
  • Superior survival rates: FOLFOX-HAIC nearly doubles median survival compared to standard systemic oral therapies.
  • Conversion surgery potential: Shrinks massive tumors to allow for potential surgical removal or transplantation.
  • Expertise infrastructure: Hospitals like Fuda Cancer Hospital utilize advanced vascular interventional therapy regularly.

Bookimed Expert Insight: While Western protocols often move to systemic therapy for stage 4 cases, Chinese centers like Fuda Cancer Hospital leverage high-volume interventional expertise. Their JCI-accredited facilities often combine HAIC with technologies like cryosurgery or NanoKnife. This aggressive multimodal strategy is why they successfully treat over 30,000 international patients with advanced stages.

Patient Consensus: Patients note that Chinese teams are much more aggressive about treating the liver directly. They often highlight that HAIC feels like a five-star hospital experience despite the intensive catheter-based nature of the treatment.

Can international patients access China's latest cancer drugs and clinical trials?

International patients can legally access approved Chinese cancer drugs through accredited medical centers. Enrollment in clinical trials is possible but complex. Access is typically managed through international departments at JCI-accredited facilities like Fuda Cancer Hospital. Success depends on genomic compatibility and strict regulatory compliance.

  • Available therapies: Access CAR-T cell therapy, PD-1 inhibitors, and targeted molecular therapies.
  • Minimally invasive options: Clinics offer NanoKnife, cryosurgery, and vascular interventional therapy for advanced stages.
  • Trial enrollment: Multi-regional clinical trials provide the highest success rate for foreign nationals.
  • Regulatory standards: Facilities like Fuda Cancer Hospital maintain JCI accreditation for international safety.

Bookimed Expert Insight: China's oncology landscape is unique because hospitals often specialize in specific ablation techniques. Fuda Cancer Hospital has treated over 30,000 international patients across 100 countries. Our data shows this high volume is due to their expertise in combining cryosurgery with NanoKnife. This specific combination is often absent in standard global protocols for stage 4 liver cancer.

Patient Consensus: Patients note that major hospitals provide high-quality rooms that feel like hotels. They emphasize the importance of having professional translation to ensure home-country doctors understand the Chinese diagnosis.

Are minimally invasive ablation technologies like NanoKnife or Cryosurgery used for Stage 4?

NanoKnife and cryosurgery are effective local therapies for stage 4 liver cancer in China. These technologies manage specific tumors within a systemic treatment plan. They help debulk larger masses and relieve symptoms. Surgeons use them when conventional surgery is not feasible.

  • NanoKnife benefit: Preserves critical structures like bile ducts and major blood vessels.
  • Cryosurgery visibility: Monitoring the formation of the ice ball ensures precise tumor destruction.
  • Palliative relief: Shrinking tumors reduces pain and pressure on surrounding organs.
  • Oligometastatic control: Targeted ablation treats limited metastases alongside systemic immunotherapy or chemotherapy.

Bookimed Expert Insight: Chinese oncology centers like Fuda Cancer Hospital offer over 10 types of minimally invasive therapies. This variety allows doctors to bypass traditional chemotherapy for some advanced cases. Dr. Liuying at Jinshazhou Hospital specifically trains other specialists in these ablation standards. This high concentration of expertise makes China a primary destination for complex, multi-modality tumor management.

Patient Consensus: Patients note that these procedures require specialized hospital stays despite being minimally invasive. They emphasize verifying the clinical team's specific experience with local ablation for liver-dominant disease.

What role does Traditional Chinese Medicine play in Stage 4 liver cancer care?

Traditional Chinese Medicine (TCM) serves as a palliative support tool for Stage 4 liver cancer. It focuses on reducing symptoms like pain or nausea. Oncology centers in China typically use it alongside immunotherapy or ablation. This integrated approach aims to improve sleep and appetite during advanced care.

  • Symptom relief: Herbs like Poria Cocos help manage fluid buildup and abdominal swelling.
  • Treatment tolerance: Spleen-nourishing formulas may reduce nausea and fatigue from systemic therapies.
  • Expert management: Clinics like Jinshazhou Hospital utilize oncology specialists trained in university settings.
  • Safety focus: Doctors monitor herbal use to prevent interference with targeted western drugs.

Bookimed Expert Insight: Data from JCI-accredited facilities like Fuda Cancer Hospital shows that successful Stage 4 care prioritizes technology over herbs. Clinicians often lead with NanoKnife or cryosurgery to control tumors before adding TCM. This sequence ensures that late-stage patients receive effective debulking before focusing solely on herbal symptom management.

Patient Consensus: Patients note that TCM-style care often makes the hospital experience feel more emotionally reassuring and familiar. While some find acupuncture helpful for relaxation, they emphasize that herbal supplements must be disclosed to avoid stressing the liver further.

Dapatkan konsultasi gratis

Pilih cara terbaik agar kami menghubungi Anda